Sage Therapeutics Inc. buy Royal Bank of Canada
Start price
13.03.23
/
50%
€42.33
Target price
13.03.24
€56.02
Performance (%)
-56.77%
End price
14.03.24
€18.30
Summary
This prediction ended on 14.03.24 with a price of €18.30. The BUY prediction by Royal_Bank_of_Canada for Sage Therapeutics Inc. performed very badly with a performance of -56.77%. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Sage Therapeutics Inc. | 0.142% | 0.142% | -62.372% |
iShares Core DAX® | 0.347% | 2.173% | 18.599% |
iShares Nasdaq 100 | 0.715% | 0.138% | 26.542% |
iShares Nikkei 225® | 1.522% | 2.003% | 13.220% |
iShares S&P 500 | 0.631% | 1.633% | 25.009% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Sage Therapeutics Inc. diskutieren
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $60.00 price target on the stock, up previously from $40.00.
Ratings data for SAGE provided by MarketBeat
In the thread Trading Sage Therapeutics Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten